Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-muscle Invasive Bladder Cancer

NCT04564781 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT04564781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04564781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Multiplex Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-muscle Invasive Bladder Cancer
Lead sponsor
Cedars-Sinai Medical Center
Phase
Observational
Overall status
Recruiting
Start date
September 18, 2020
Completion date
February 28, 2030
Enrollment
400 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer